Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mito-CP
- Development stage
- Preclinical
- Lead developer
- Medical College of Wisconsin
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Mito-CP is a mitochondria-targeted nitroxide antioxidant designed to accumulate within the mitochondrial matrix. It consists of a carboxy-proxyl (CP) nitroxide moiety covalently linked to a triphenylphosphonium (TPP+) cation, which utilizes the negative mitochondrial membrane potential for selective uptake. Mito-CP acts as a superoxide dismutase (SOD) mimetic and a scavenger of reactive oxygen species (ROS), particularly mitochondrial superoxide. In preclinical research, it has been investigated for its ability to protect against alcohol-induced mitochondrial dysfunction and esophageal stem cell expansion. Additionally, it has shown synergistic effects when combined with glycolytic inhibitors (such as 2-deoxy-D-glucose or 3-bromopyruvate) to induce ATP depletion and cell death in pancreatic cancer cell lines.
- Other names
- 3-Carboxy-proxyl-triphenylphosphoniumMito-Carboxy Proxyl3-Carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxy triphenylphosphonium
02
Targets
ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on Mito-CP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mito-CP.